Article Text

Download PDFPDF
The N-Terminally Truncated p53 Isoform Δ40p53 Influences Prognosis in Mucinous Ovarian Cancer
  1. Gerda Hofstetter, MD*,
  2. Astrid Berger, MD*,
  3. Regina Berger, PhD*,
  4. Arijana Zorić, PhD,
  5. Elena I. Braicu, MD,
  6. Daniel Reimer, MD*,
  7. Heidi Fiegl, PhD*,
  8. Christian Marth, MD*,
  9. Alain G. Zeimet, MD*,
  10. Hanno Ulmer, PhD§,
  11. Ute Moll, MD,
  12. Robert Zeillinger, PhD,# and
  13. Nicole Concin, MD*
  1. * Department of Gynecology and Obstetrics, Medical University Innsbruck, Innsbruck, Austria;
  2. Laboratory of Molecular Oncology, Department of Molecular Medicine, Rudjer Boskovic Institute, Zagreb, Croatia;
  3. Department of Gynecology, European Competence Center for Ovarian Cancer, Charité University-Hospital, Berlin, Germany;
  4. § Department of Medical Statistics, Informatics, and Health Economics, Medical University Innsbruck, Innsbruck, Austria;
  5. Department ofPathology, Stony Brook University, Stony Brook, New York; and
  6. Department of Obstetrics and Gynecology, Molecular Oncology Group, Medical University of Vienna; and
  7. # Ludwig Boltzmann Gesellschaft, Cluster Translational Oncology, Vienna, Austria.
  1. Address correspondence and reprint requests to Nicole Concin, MD, Department of Gynecology and Obstetrics, Medical University Innsbruck, Anichstrasse 35, A-6020 Innsbruck, Austria. E-mail: nicole.concin{at}i-med.ac.at.

Abstract

Objective The tumor suppressor p53 generates the N-terminally truncated isoforms Δ40p53 and Δ133p53 that possess the ability to modulate p53 function in vitro. The aim of the present study was to evaluate the clinical relevance of p53 isoforms in the main histological subtypes of ovarian cancer.

Methods Δ40p53, Δ133p53, and full-length p53 (FLp53) expression was determined in 45 mucinous, 30 endometrioid, and 91 serous ovarian cancer specimens as well as 42 normal ovarian tissues using reverse transcriptase–quantitative polymerase chain reaction. In a subgroup of mucinous ovarian cancer cases, Δ40p53 expression was examined using Western blot analysis. A functional yeast-based assay and subsequent sequencing were performed to analyze the p53 mutational status.

Results In endometrioid cancer specimens, Δ133p53 expression was significantly lower than in mucinous and serous cases (P = 0.016) or in normal tissues (P = 0.004). Mucinous cancer samples showed elevated Δ40p53 expression as compared with normal ovarian tissues (P = 0.003). In addition, high Δ40p53 expression constituted an independent prognostic marker for recurrence-free but not for overall survival in patients with mucinous ovarian cancer (hazard ratio, 0.267; 95% confidence interval, 0.094–0.756 [P = 0.013]; hazard ratio, 0.453, 95% confidence interval, 0.193–1.064 [P = 0.069]). Western blot analysis confirmed the presence of p53β and Δ40p53α in a subset of patients with mucinous ovarian cancer. Expression of p53 isoforms was not associated with p53 mutational status or clinicopathologic parameters.

Conclusions We show that expression of p53 isoforms differs in histological subtypes, thus supporting the hypothesis that histological subtypes represent distinct disease entities. In addition, we provide first evidence for a favorable role of Δ40p53 in patients with mucinous ovarian cancer.

  • p53 Isoforms
  • Δ40p53
  • Ovarian cancer
  • Mucinous ovarian cancer

Statistics from Altmetric.com

Footnotes

  • The authors declare that there are no conflicts of interest.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.